153710 — Optipharm Co Share Price
Last trade - 00:00- KR₩79bn
- KR₩75bn
- KR₩17bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.32 | ||
| Price to Tang. Book | 3.36 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.25 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -6.91% | ||
| Return on Equity | -9.58% | ||
| Operating Margin | -10.17% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 13,652.79 | 13,045.85 | 14,258.44 | 16,008.2 | 17,372.57 | n/a | n/a | 4.47% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Optipharm.CO.,LTD is a Korea-based company mainly engaged in the production and sale of veterinary drugs. The Company operates its business through two segments. The Sale Business segment is involved in the provision of livestock disease appraisal services, animal drug distribution, and the manufacturing and sale of feed additives. The New Business segment is engaged in research and development of heterologous organisms, virus like particle (VLP) vaccines, and human diagnostic kits. Heterogeneous organ products include heterologous skin, xenogeneic islets and xenogeneic corneal products, among others. VLP vaccines include VLP based animal combined vaccines and human papillomavirus (HPV) vaccines for the human body, among others. Human body diagnostic kits include human breast cancer and cervical cancer diagnostic reagents, among others. The Company distributes its products within the domestic market and to overseas markets.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- July 27th, 2000
- Public Since
- October 26th, 2018
- No. of Shareholders
- 9,517
- No. of Employees
- 77
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 14,669,958
- Address
- 63, Osongsaengmyeong 6-ro, CHEONGJU, 28158
- Web
- https://www.optipharm.co.kr/NEW/ko/
- Phone
- +82 432497500
- Auditors
- Gwanggyo Accounting Corporation
Upcoming Events for 153710
Similar to 153710
AbClon
Korea Exchange - KOSDAQ
ADBiotech Co
Korea Exchange - KOSDAQ
AHN-GOOK PHARMACEUTICAL Co
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
Aminologics Co
Korea Exchange - KOSDAQ
FAQ
As of Today at 22:29 UTC, shares in Optipharm Co are trading at KR₩5,380. This share price information is delayed by 15 minutes.
Shares in Optipharm Co last closed at KR₩5,380 and the price had moved by -27.49% over the past 365 days. In terms of relative price strength the Optipharm Co share price has underperformed the FTSE Developed Asia Pacific Index by -38.09% over the past year.
There is no consensus recommendation for this security.
Find out moreOptipharm Co does not currently pay a dividend.
Optipharm Co does not currently pay a dividend.
Optipharm Co does not currently pay a dividend.
To buy shares in Optipharm Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩5,380, shares in Optipharm Co had a market capitalisation of KR₩79bn.
Here are the trading details for Optipharm Co:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 153710
Based on an overall assessment of its quality, value and momentum Optipharm Co is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Optipharm Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -24.92%.
As of the last closing price of KR₩5,380, shares in Optipharm Co were trading -16.99% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Optipharm Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩5,380.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Optipharm Co's management team is headed by:
- Seong Jun Han - CCE
- Hyeon Yil Kim - CCE